SGMT NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Sagimet Biosciences Inc. Series A Common Stock · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 7.11 USD
0.6% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 12.5% above the Trend Line and sits at 46.9% of its 52-week range. The latest completed week returned 0.6%, after a -6.6% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 47/100 conviction, while the latest news-sentiment score is 51/100. Near-term considerations: volume confirmation is below normal; earnings are due in 10d.

Setup score 39 out of 100
Latest Close 7.11 USD 31 Jul 2026
1W Return 0.6% latest completed week
4W Return -6.6% short-term follow-through
12W Return -7.8% quarterly tape
Trend Breadth 50.0% 26 of 52 weeks active
Volume Ratio 0.5x vs 13-week average
What is working
  • The trend backdrop is active with a 9-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The share remains more than 20% below its 52-week high.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 0.6% Latest completed week; four-week move -6.6%. Indicator stack 59/55 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 47/100 conviction; expected move 18.8%. News sentiment 51/100 66 relevant articles in the latest sentiment read. Event risk 10d Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 12.5% above the Trend Line and sits at 46.9% of its 52-week range. The latest completed week returned 0.6%, after a -6.6% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.5x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.5712-week average 0.44

12-week confirmation

Trend active9/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership1/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.57Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -6.6% over four weeks, -7.8% over 12 weeks, and -13.8% over one year. The current trend has remained active for 9 consecutive weeks.

Performance by holding period

1W0.6%
4W-6.6%
12W-7.8%
26W25.4%
52W-13.8%
Active trend streak9 weeks
Active weeks in one year26
Trend breadth50.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.45Latest activity-pressure read.
Pressure change-38.1%Four-week change in activity pressure.
Leadership-2.88Latest relative-leadership reading.
RS change27.6%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 64% Model confidence 61%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength39/100Blend of value, momentum, and quality. Underlying universe rank 62; rank 1 is best.
Value45/100Relative valuation strength. Underlying universe rank 56; rank 1 is best.
Quality43/100Profitability and accounting quality. Underlying universe rank 58; rank 1 is best.
Momentum45/100Medium-term price momentum. Underlying universe rank 56; rank 1 is best.
Growth45/100Revenue and earnings growth. Underlying universe rank 56; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-9.9%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-55.5%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
1/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.8x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

SGMT shows volatility options pressure with a 47/100 conviction score, put-call volume ratio of 0.13, expected move of 18.8%, and Sharemaestro trend signal active.

Conviction47/100
Expected move18.8%
Put/call volume0.13
Pressure80
Speculation4
Volatility96
Trend agreement9
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment51/100

Weighted news tone is neutral across 66 relevant articles.

10 positive · 52 neutral · 4 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings10dNext report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
Options expected move18.8%Nearest-chain priced movement where available.
52-week drawdown-29.3%Distance below the 52-week high.
13-week volatility5.8%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher14 of 2612 weeks finished lower.
Best week+29.9%Week of 1 May.
Worst week-10.5%Week of 15 May.
Latest week+0.6%Week of 31 Jul.

Shape of recent returns

Strong gains8
Modest gains6
Flat weeks0
Modest losses4
Sharp losses8
Recent vol5.8%13-week weekly-return volatility.
Base vol8.8%52-week weekly-return volatility.
Up/down split24/27Count of positive and negative weeks in the 52-week window.
Average skew7.3% / -6.3%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape43/100

Trend, activity pressure, participation, and risk combine to a 43/100 tape read.

 Indicator analysis60/100

Latest 12-week confirmation: trend 9/12, activity pressure 12/12, relative leadership 1/12.

Activity pressure 0.57; No reversal markers Factors42/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 51; Small Cap Core rank 58 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options36/100

SGMT shows volatility options pressure with a 47/100 conviction score, put-call volume ratio of 0.13, expected move of 18.8%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 18.8% Sentiment51/100

Weighted news tone is neutral across 66 relevant articles.

BlackRock (NYSE: BLK) reports 7.8% beneficial stake in Sagimet Biosciences (SGMT) Insiders50/100

No recent insider transaction evidence is stored.

 Earnings10d

Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20267.11 USD0.6%6.32 USD5.84 USD0.45-2.882.4MOn
24 Jul 20267.07 USD-9.6%6.28 USD5.90 USD0.69-3.704.0MOn
17 Jul 20267.82 USD6.1%6.25 USD5.96 USD0.883.365.8MOn
10 Jul 20267.37 USD-3.2%6.20 USD6.01 USD0.78-7.555.1MOn
3 Jul 20267.61 USD7.8%6.16 USD6.06 USD0.73-3.984.4MOn
26 Jun 20267.06 USD5.7%6.12 USD6.05 USD0.65-10.8113.3MOn
19 Jun 20266.68 USD3.1%6.12 USD6.05 USD0.67-20.016.2MOn
12 Jun 20266.48 USD-4.1%6.12 USD6.04 USD0.79-21.353.3MOn
5 Jun 20266.76 USD-7.3%6.16 USD6.04 USD0.90-17.003.3MOn
29 May 20267.29 USD2.8%6.19 USD6.04 USD1.03-14.663.0MOff
22 May 20267.09 USD2.8%6.23 USD6.03 USD1.10-14.174.5MOff
15 May 20266.90 USD-10.5%6.30 USD6.02 USD0.95-15.023.9MOff
8 May 20267.71 USD1.3%6.31 USD6.01 USD0.91-4.785.8MOff
1 May 20267.61 USD29.9%6.31 USD6.00 USD0.54-0.1558.8MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.